What's in a Name? Roles of RFamide-Related Peptides Beyond Gonadotrophin Inhibition

Journal of Neuroendocrinology

Volumn 28, Issue 9, 2016, Pages

  Kim, J S ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

gonadotrophin inhibitory hormone; gonadotrophin releasing hormone; neuropeptide FF; RFamide related peptide

Indexed keywords

GONADOTROPIN; NEUROPEPTIDE; NEUROPEPTIDE FF; NEUROPEPTIDE RECEPTOR; OPIATE; RFAMIDE RELATED PEPTIDE; UNCLASSIFIED DRUG; NEUROPEPTIDE FF RECEPTOR; RFAMIDE PEPTIDE;

ANXIETY; HORMONE INHIBITION; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REPRODUCTION; REVIEW; STRESS; ANIMAL; BRAIN; GONAD; GONADOTROPIN SECRETING CELL; HYPOPHYSIS; HYPOTHALAMUS; INNERVATION; MENTAL STRESS; NERVE TRACT; PHYSIOLOGY;

ANIMALS; ANXIETY; BRAIN; GONADOTROPHS; GONADS; HUMANS; HYPOTHALAMUS; NEURAL PATHWAYS; NEUROPEPTIDES; PITUITARY GLAND; RECEPTORS, NEUROPEPTIDE; REPRODUCTION; STRESS, PSYCHOLOGICAL;

EID: 84986556338     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/jne.12407     Document Type: Review

References (128)

1. Hinuma S, Shintani Y, Fukusumi S, Iijima N, Matsumoto Y, Hosoya M, Fujii R, Watanabe T, Kikuchi K, Terao Y. New neuropeptides containing carboxy-terminal RFamide and their receptor in mammals. Nat Cell Biol 2000; 2: 703–708.
2. Liu Q, Guan X-M, Martin WJ, McDonald TP, Clements MK, Jiang Q, Zeng Z, Jacobson M, Williams DL, Yu H. Identification and characterization of novel mammalian neuropeptide FF-like peptides that attenuate morphine-induced antinociception. J Biol Chem 2001; 276: 36961–36969.
3. Tsutsui K, Saigoh E, Ukena K, Teranishi H, Fujisawa Y, Kikuchi M, Ishii S, Sharp PJ. A novel avian hypothalamic peptide inhibiting gonadotropin release. Biochem Biophys Res Commun 2000; 275: 661–667.
4. Tsutsui K, Ubuka T, Son YL, Bentley GE, Kriegsfeld LJ. Contribution of GnIH research to the progress of reproductive neuroendocrinology. Front Endocrinol 2015; 6: 179.
5. Vilim FS, Aarnisalo AA, Nieminen M-L, Lintunen M, Karlstedt K, Kontinen VK, Kalso E, Panula P, Ziff E. Gene for pain modulatory neuropeptide NPFF: induction in spinal cord by noxious stimuli. Mol Pharmacol 1999; 55: 804–811.
6. Bonini JA, Jones KA, Adham N, Forray C, Artymyshyn R, Durkin MM, Smith KE, Tamm JA, Boteju LW, Lakhlani PP. Identification and characterization of two G protein-coupled receptors for neuropeptide FF. J Biol Chem 2000; 275: 39324–39331.
7. Christian CA, Moenter SM. The neurobiology of preovulatory and estradiol-induced gonadotropin-releasing hormone surges. Endocr Rev 2010; 31: 544–577.
8. Leon S, Tena-Sempere M. Dissecting the roles of gonadotropin-inhibitory hormone in mammals: studies using pharmacological tools and genetically modified mouse models. Front Endocrinol 2016; 6: 189.
9. Herbison AE. Physiology of the gonadotropin-releasing hormone neuronal network. In: Plant TM, Zeleznik AJ, eds. Knobil and Neill's Physiology of Reproduction. 4th edn. Vol. 1. 399–467. Academic Press, 2015.
10. Simonin F, Schmitt M, Laulin J-P, Laboureyras E, Jhamandas JH, MacTavish D, Matifas A, Mollereau C, Laurent P, Parmentier M. RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci USA 2006; 103: 466–471.
11. Caraty A, Blomenröhr M, Vogel G, Lomet D, Briant C, Beltramo M. RF9 powerfully stimulates gonadotrophin secretion in the ewe: evidence for a seasonal threshold of sensitivity. J Neuroendocrinol 2012; 24: 725–736.
12. Glanowska KM, Burger LL, Moenter SM. Development of gonadotropin-releasing hormone secretion and pituitary response. J Neurosci 2014; 34: 15060–15069.
13. Pineda R, Garcia-Galiano D, Sanchez-Garrido M, Romero M, Ruiz-Pino F, Aguilar E, Dijcks F, Blomenrohr M, Pinilla L, Van Noort P. Characterization of the potent gonadotropin-releasing activity of RF9, a selective antagonist of RF-amide-related peptides and neuropeptide FF receptors: physiological and pharmacological implications. Endocrinology 2010; 151: 1902–1913.
14. Rizwan MZ, Poling MC, Corr M, Cornes PA, Augustine RA, Quennell JH, Kauffman AS, Anderson GM. RFamide-related peptide-3 receptor gene expression in GnRH and kisspeptin neurons and GnRH-dependent mechanism of action. Endocrinology 2012; 153: 3770–3779.
15. García-Galiano D, van Ingen Schenau D, Leon S, Krajnc-Franken MA, Manfredi-Lozano M, Romero-Ruiz A, Navarro VM, Gaytan F, van Noort PI, Pinilla L. Kisspeptin signaling is indispensable for neurokinin B, but not glutamate, stimulation of gonadotropin secretion in mice. Endocrinology 2011; 153: 316–328.
16. Bentley GE, Tsutsui K, Kriegsfeld LJ. Recent studies of gonadotropin-inhibitory hormone (GnIH) in the mammalian hypothalamus, pituitary and gonads. Brain Res 2010; 1364: 62–71.
17. Kriegsfeld LJ, Gibson EM, Williams W, Zhao S, Mason AO, Bentley GE, Tsutsui K. The roles of RFamide-related peptide-3 in mammalian reproductive function and behaviour. J Neuroendocrinol 2010; 22: 692–700.
18. Pineda R, Garcia-Galiano D, Sanchez-Garrido MA, Romero M, Ruiz-Pino F, Aguilar E, Dijcks FA, Blomenröhr M, Pinilla L, Van Noort P. Characterization of the inhibitory roles of RFRP3, the mammalian ortholog of GnIH, in the control of gonadotropin secretion in the rat: in vivo and in vitro studies. Am J Physiol Endocrinol Metab 2010; 299: E39–E46.
19. León S, García-Galiano D, Ruiz-Pino F, Barroso A, Manfredi-Lozano M, Romero-Ruiz A, Roa J, Vázquez MJ, Gaytan F, Blomenrohr M. Physiological roles of gonadotropin-inhibitory hormone signaling in the control of mammalian reproductive axis: studies in the NPFF1 receptor null mouse. Endocrinology 2014; 155: 2953–2965.
20. Liu X, Herbison AE. RF9 excitation of GnRH neurons is dependent upon Kiss1r in the adult male and female mouse. Endocrinology 2014; 155: 4915–4924.
21. Sahin Z, Canpolat S, Ozcan M, Ozgocer T, Kelestimur H. Kisspeptin antagonist prevents RF9-induced reproductive changes in female rats. Reproduction 2015; 149: 465–473.
22. Kim JS, Brownjohn PW, Dyer BS, Beltramo M, Walker CS, Hay DL, Painter GF, Tyndall JD, Anderson GM. Anxiogenic and stressor effects of the hypothalamic neuropeptide RFRP-3 are overcome by the NPFFR antagonist GJ14. Endocrinology 2015; 156: 4152–4162.
23. Min L, Leon S, Li H, Pinilla L, Carroll RS, Tena-Sempere M, Kaiser UB. RF9 acts as a KISS1R agonist in vivo and in vitro. Endocrinology 2015; 156: 4639–4648.
24. Decourt C, Anger K, Robert V, Lomet D, Bartzen-Sprauer J, Caraty A, Dufourny L, Anderson G, Beltramo M. No evidence that RFamide related peptide 3 directly modulates LH secretion in the ewe. Endocrinology 2016; 157: 1566–1575.
25. Mollereau C, Mazarguil H, Marcus D, Quelven I, Kotani M, Lannoy V, Dumont Y, Quirion R, Detheux M, Parmentier M. Pharmacological characterization of human NPFF 1 and NPFF 2 receptors expressed in CHO cells by using NPY Y 1 receptor antagonists. Eur J Pharmacol 2002; 451: 245–256.
26. Rudolf K, Eberlein W, Engel W, Wieland HA, Willim KD, Entzeroth M, Wienen W, Beck-Sickinger AG, Doods HN. The first highly potent and selective non-peptide neuropeptide Y Y 1 receptor antagonist: BIBP3226. Eur J Pharmacol 1994; 271: R11–R13.
27. Leupen SM, Besecke LM, Levine JE. Neuropeptide Y Y1-receptor stimulation is required for physiological amplification of preovulatory luteinizing hormone surges 1. Endocrinology 1997; 138: 2735–2739.
28. Murakami M, Matsuzaki T, Iwasa T, Yasui T, Irahara M, Osugi T, Tsutsui K. Hypophysiotropic role of RFamide-related peptide-3 in the inhibition of LH secretion in female rats. J Endocrinol 2008; 199: 105–112.
29. Anderson GM, Relf H-L, Rizwan MZ, Evans JJ. Central and peripheral effects of RFamide-related peptide-3 on luteinizing hormone and prolactin secretion in rats. Endocrinology 2009; 150: 1834–1840.
30. Ancel C, Bentsen AH, Sébert M-E, Tena-Sempere M, Mikkelsen JD, Simonneaux V. Stimulatory effect of RFRP-3 on the gonadotrophic axis in the male Syrian hamster: the exception proves the rule. Endocrinology 2012; 153: 1352–1363.
31. Ubuka T, Inoue K, Fukuda Y, Mizuno T, Ukena K, Kriegsfeld LJ, Tsutsui K. Identification, expression, and physiological functions of Siberian hamster gonadotropin-inhibitory hormone. Endocrinology 2011; 153: 373–385.
32. Ducret E, Anderson GM, Herbison AE. RFamide-related peptide-3, a mammalian gonadotropin-inhibitory hormone ortholog, regulates gonadotropin-releasing hormone neuron firing in the mouse. Endocrinology 2009; 150: 2799–2804.
33. Wu M, Dumalska I, Morozova E, Van Den Pol AN, Alreja M. Gonadotropin inhibitory hormone inhibits basal forebrain vGluT2-gonadotropin-releasing hormone neurons via a direct postsynaptic mechanism. J Physiol 2009; 587: 1401–1411.
34. Rivier C, Rivest S. Effect of stress on the activity of the hypothalamic-pituitary-gonadal axis: peripheral and central mechanisms. Biol Reprod 1991; 45: 523–532.
35. Rivier C, Vale W. Influence of corticotropin-releasing factor on reproductive functions in the rat. Endocrinology 1984; 114: 914–921.
36. Schneider JE. Energy balance and reproduction. Physiol Behav 2004; 81: 289–317.
37. Hill JW, Elmquist JK, Elias CF. Hypothalamic pathways linking energy balance and reproduction. Am J Physiol-Endocrinol Metab 2008; 294: E827–E832.
38. Jaroslawska J, Chabowska-Kita A, Kaczmarek MM, Kozak LP. Npvf: hypothalamic biomarker of ambient temperature independent of nutritional status. PLoS Genet 2015; 11: e1005287.
39. Kirby ED, Geraghty AC, Ubuka T, Bentley GE, Kaufer D. Stress increases putative gonadotropin inhibitory hormone and decreases luteinizing hormone in male rats. Proc Natl Acad Sci USA 2009; 106: 11324–11329.
40. Geraghty AC, Muroy SE, Zhao S, Bentley GE, Kriegsfeld LJ, Kaufer D. Knockdown of hypothalamic RFRP3 prevents chronic stress-induced infertility and embryo resorption. eLife 2015; 4: e04316.
41. Elshourbagy NA, Ames RS, Fitzgerald LR, Foley JJ, Chambers JK, Szekeres PG, Evans NA, Schmidt DB, Buckley PT, Dytko GM. Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor. J Biol Chem 2000; 275: 25965–25971.
42. Yang H, Fratta W, Majane E, Costa E. Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc Natl Acad Sci USA 1985; 82: 7757–7761.
43. Tang J, Yang H, Costa E. Inhibition of spontaneous and opiate-modified nociception by an endogenous neuropeptide with Phe-Met-Arg-Phe-NH2-like immunoreactivity. Proc Natl Acad Sci USA 1984; 81: 5002–5005.
44. Gicquel S, Mazarguil H, Allard M, Simonnet G, Zajac J-M. Analogues of F8Famide resistant to degradation, with high affinity and in vivo effects. Eur J Pharmacol 1992; 222: 61–67.
45. Allard M, Geoffre S, Legendre P, Vincent J, Simonnet G. Characterization of rat spinal cord receptors to FLFQPQRFamide, a mammalian morphine modulating peptide: a binding study. Brain Res 1989; 500: 169–176.
46. Rothman RB. A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse 1992; 12: 129–138.
47. Moulédous L, Mollereau C, Zajac JM. Opioid-modulating properties of the neuropeptide FF system. BioFactors 2010; 36: 423–429.
48. Kersanté F, Mollereau C, Zajac J-M, Roumy M. Anti-opioid activities of NPFF1 receptors in a SH-SY5Y model. Peptides 2006; 27: 980–989.
49. Roumy M, Garnier M, Zajac J-M. Neuropeptide FF receptors 1 and 2 exert an anti-opioid activity in acutely dissociated rat dorsal raphe and periventricular hypothalamic neurones. Neurosci Lett 2003; 348: 159–162.
50. Elhabazi K, Humbert J-P, Bertin I, Schmitt M, Bihel F, Bourguignon J-J, Bucher B, Becker JA, Sorg T, Meziane H. Endogenous mammalian RF-amide peptides, including PrRP, kisspeptin and 26RFa, modulate nociception and morphine analgesia via NPFF receptors. Neuropharmacology 2013; 75: 164–171.
51. Roumy M, Lorenzo C, Mazères S, Bouchet S, Zajac J-M, Mollereau C. Physical association between neuropeptide FF and μ-opioid receptors as a possible molecular basis for anti-opioid activity. J Biol Chem 2007; 282: 8332–8342.
52. Kotlinska J, Pachuta A, Dylag T, Silberring J. Neuropeptide FF (NPFF) reduces the expression of morphine-but not of ethanol-induced conditioned place preference in rats. Peptides 2007; 28: 2235–2242.
53. Marchand S, Betourne A, Marty V, Daumas S, Halley H, Lassalle J-M, Zajac J-M, Frances B. A neuropeptide FF agonist blocks the acquisition of conditioned place preference to morphine in C57Bl/6J mice. Peptides 2006; 27: 964–972.
54. Kersanté F, Wang J-Y, Chen J-C, Mollereau C, Zajac J-M. Anti-opioid effects of neuropeptide FF receptors in the ventral tegmental area. Neurosci Lett 2011; 488: 305–309.
55. Ukena K, Tsutsui K. Distribution of novel RFamide-related peptide-like immunoreactivity in the mouse central nervous system. Neurosci Lett 2001; 300: 153–156.
56. Yang H-Y, Iadarola M. Activation of spinal neuropeptide FF and the neuropeptide FF receptor 2 during inflammatory hyperalgesia in rats. Neuroscience 2003; 118: 179–187.
57. Mollereau C, Mazarguil H, Zajac J-M, Roumy M. Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells. Mol Pharmacol 2005; 67: 965–975.
58. 2+ in mouse spinal ganglion neurons. Eur J Pharmacol 1996; 306: 291–295.
59. 2+ channels in rat spinal ganglion neurones. NeuroReport 1996; 7: 2979–2982.
60. Roumy M, Zajac J-M. Neuropeptide FF selectively attenuates the effects of nociceptin on acutely dissociated neurons of the rat dorsal raphe nucleus. Brain Res 1999; 845: 208–214.
61. Findeisen M, Rathmann D, Beck-Sickinger AG. RFamide peptides: structure, function, mechanisms and pharmaceutical potential. Pharmaceuticals 2011; 4: 1248–1280.
62. Simonin F. Neuropeptide FF receptors as therapeutic targets. Drugs Future 2006; 31: 603.
63. Max MB, Stewart WF. The molecular epidemiology of pain: a new discipline for drug discovery. Nat Rev Drug Discovery 2008; 7: 647–658.
64. Gelot A, Francés B, Gicquel S, Zajac J-M. Antisense oligonucleotides to human SQA-neuropeptide FF decrease morphine tolerance and dependence in mice. Eur J Pharmacol 1998; 358: 203–206.
65. Lake JR, Hammond MV, Shaddox RC, Hunsicker LM, Yang H-YT, Malin DH. IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat. Neurosci Lett 1991; 132: 29–32.
66. Elhabazi K, Trigo J, Mollereau C, Mouledous L, Zajac JM, Bihel F, Schmitt M, Bourguignon J, Meziane H, Petit-demoulière B. Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments. Br J Pharmacol 2011; 165: 424–435.
67. Milanes M, Laorden M, Chapleur-Chateau M, Burlet A. Alterations in corticotropin-releasing factor and vasopressin content in rat brain during morphine withdrawal: correlation with hypothalamic noradrenergic activity and pituitary-adrenal response. J Pharmacol Exp Ther 1998; 285: 700–706.
68. Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs 2003; 35: 253–259.
69. Malin DH, Lake JR, Hammond MV, Fowler DE, Rogillio RB, Brown SL, Sims JL, Leecraft BM, Yang H-YT. FMRF-NH 2-like mammalian octapeptide: possible role in opiate dependence and abstinence. Peptides 1990; 11: 969–972.
70. Kaewwongse M, Takayanagi Y, Onaka T. Effects of RFamide-related peptide (RFRP)-1 and RFRP-3 on oxytocin release and anxiety-related behaviour in rats. J Neuroendocrinol 2011; 23: 20–27.
71. Jászberényi M, Bagosi Z, Thurzó B, Földesi I, Szabó G, Telegdy G. Endocrine, behavioral and autonomic effects of neuropeptide AF. Horm Behav 2009; 56: 24–34.
72. Palotai M, Telegdy G, Tanaka M, Bagosi Z, Jászberényi M. Neuropeptide AF induces anxiety-like and antidepressant-like behavior in mice. Behav Brain Res 2014; 274: 264–269.
73. Malin DH, Lake JR, Fowler DE, Hammond MV, Brown SL, Leyva JE, Prasco PE, Dougherty TM. FMRF-NH 2-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat. Peptides 1990; 11: 277–280.
74. Roumy M, Zajac J-M. Neuropeptide FF, pain and analgesia. Eur J Pharmacol 1998; 345: 1–11.
75. Jhamandas K, Milne B, Sutak M, Gouarderes C, Zajac J-M, Yang H-Y. Facilitation of spinal morphine analgesia in normal and morphine tolerant animals by neuropeptide SF and related peptides. Peptides 2006; 27: 953–963.
76. Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci 2009; 10: 397–409.
77. Jhamandas JH, Simonin F, Bourguignon J-J, Harris KH. Neuropeptide FF and neuropeptide VF inhibit GABAergic neurotransmission in parvocellular neurons of the rat hypothalamic paraventricular nucleus. Am J Physiol Regul Integr Comp Physiol 2007; 292: R1872–R1880.
78. Lee V, Maguire J. The impact of tonic GABAA receptor-mediated inhibition on neuronal excitability varies across brain region and cell type. Front Neural Circuits 2014; 8: 3.
79. Wamsteeker JI, Bains JS. A synaptocentric view of the neuroendocrine response to stress. Eur J Neurosci 2010; 32: 2011–2021.
80. Petraglia F, Sutton S, Vale W, Plotsky P. Corticotropin-releasing factor decreases plasma luteinizing hormone levels in female rats by inhibiting gonadotropin-releasing hormone release into hypophysial-portal circulation. Endocrinology 1987; 120: 1083–1088.
81. Rivest S, Plotsky P, Rivier C. CRF alters the infundibular LHRH secretory system from the medial preoptic area of female rats: possible involvement of opioid receptors. Neuroendocrinology 1993; 57: 236–246.
82. Tye KM, Prakash R, Kim S-Y, Fenno LE, Grosenick L, Zarabi H, Thompson KR, Gradinaru V, Ramakrishnan C, Deisseroth K. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 2011; 471: 358–362.
83. Kim S-Y, Adhikari A, Lee SY, Marshel JH, Kim CK, Mallory CS, Lo M, Pak S, Mattis J, Lim BK. Diverging neural pathways assemble a behavioural state from separable features in anxiety. Nature 2013; 496: 219–223.
84. Davis M, Walker DL, Lee Y. Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Ann NY Acad Sci 1997; 821: 305–331.
85. Kotlinska J, Gibula-Bruzda E, Koltunowska D, Raoof H, Suder P, Silberring J. Modulation of neuropeptide FF (NPFF) receptors influences the expression of amphetamine-induced conditioned place preference and amphetamine withdrawal anxiety-like behavior in rats. Peptides 2012; 33: 156–163.
86. Kotlinska J, Pachuta A, Bochenski M, Silberring J. Dansyl-PQRamide, a putative antagonist of NPFF receptors, reduces anxiety-like behavior of ethanol withdrawal in a plus-maze test in rats. Peptides 2009; 30: 1165–1172.
87. Douglas AJ, Brunton PJ, Bosch OJ, Russell JA, Neumann ID. Neuroendocrine responses to stress in mice: hyporesponsiveness in pregnancy and parturition. Endocrinology 2003; 144: 5268–5276.
88. Bailey CC, Kitchen I. Developmental responses to opioids reveals a lack of effect on stress-induced corticosterone levels in neonatal rats. Br J Pharmacol 1987; 91: 119–125.
89. Janssens C, Helmond FA, Loyens L, Schouten W, Wiegant VM. Chronic stress increases the opioid-mediated inhibition of the pituitary-adrenocortical response to acute stress in pigs. Endocrinology 1995; 136: 1468–1473.
90. Cohen MR, Cohen RM, Pickar D, Weingartner H, Murphy DL. High-dose naloxone infusions in normals: dose-dependent behavioral, hormonal, and physiological responses. Arch Gen Psychiatry 1983; 40: 613–619.
91. Volavka J, Cho D, Mallya A, Bauman J. Naloxone increases ACTH and cortisol levels in man. N Engl J Med 1979; 300: 1056–1057.
92. Stacher G, Abatzi T-A, Schulte F, Schneider C, Stacher-Janotta G, Gaupmann G, Mittelbach G, Steinringer H. Naloxone does not alter the perception of pain induced by electrical and thermal stimulation of the skin in healthy humans. Pain 1988; 34: 271–276.
93. Grevert P, Goldstein A. Effects of naloxone on experimentally induced ischemic pain and on mood in human subjects. Proc Natl Acad Sci USA 1977; 74: 1291–1294.
94. Ceccatelli S, Millhorn D, Hökfelt T, Goldstein M. Evidence for the occurrence of an enkephalin-like peptide in adrenaline and noradrenaline neurons of the rat medulla oblongata. Exp Brain Res 1989; 74: 631–640.
95. Ågmo A, Galvan A, Heredia A, Morales M. Naloxone blocks the antianxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review. Psychopharmacology 1995; 120: 186–194.
96. Onaka T, Luckman S, Guevara-Guzman R, Ueta Y, Kendrick K, Leng G. Presynaptic actions of morphine: blockade of cholecystokinin-induced noradrenaline release in the rat supraoptic nucleus. J Physiol 1995; 482: 69.
97. Douglas AJ, Russell JA. Endogenous opioid regulation of oxytocin and ACTH secretion during pregnancy and parturition. Prog Brain Res 2001; 133: 67–82.
98. Masotto C, Sahu A, Dube M, Kalra S. A decrease in opioid tone amplifies the luteinizing hormone surge in estrogen-treated ovariectomized rats: comparisons with progesterone effects. Endocrinology 1990; 126: 18–25.
99. Allen L, Kalra S. Evidence that a decrease in opioid tone may evoke preovulatory luteinizing hormone release in the rat. Endocrinology 1986; 118: 2375–2381.
100. Gabriel SM, Berglund LA, Simpkins JW. A decline in endogenous opioid influence during the steroid-induced hypersecretion of luteinizing hormone in the rat. Endocrinology 1986; 118: 558–561.
101. Roa J, Herbison AE. Direct regulation of GnRH neuron excitability by arcuate nucleus POMC and NPY neuron neuropeptides in female mice. Endocrinology 2012; 153: 5587–5599.
102. Osugi T, Ukena K, Sower SA, Kawauchi H, Tsutsui K. Evolutionary origin and divergence of PQRFamide peptides and LPXRFamide peptides in the RFamide peptide family. FEBS J 2006; 273: 1731–1743.
103. Daukss D, Gazda K, Kosugi T, Osugi T, Tsutsui K, Sower SA. Effects of lamprey PQRFamide peptides on brain gonadotropin-releasing hormone concentrations and pituitary gonadotropin-β mRNA expression. Gen Comp Endocrinol 2012; 177: 215–219.
104. Saito TH, Nakane R, Akazome Y, Abe H, Oka Y. Electrophysiological analysis of the inhibitory effects of FMRFamide-like peptides on the pacemaker activity of gonadotropin-releasing hormone neurons. J Neurophysiol 2010; 104: 3518–3529.
105. Umatani C, Abe H, Oka Y. Neuropeptide RFRP inhibits the pacemaker activity of terminal nerve GnRH neurons. J Neurophysiol 2013; 109: 2354–2363.
106. Murase T, Arima H, Kondo K, Oiso Y. Neuropeptide FF reduces food intake in rats. Peptides 1996; 17: 353–354.
107. Sunter D, Hewson AK, Lynam S, Dickson SL. Intracerebroventricular injection of neuropeptide FF, an opioid modulating neuropeptide, acutely reduces food intake and stimulates water intake in the rat. Neurosci Lett 2001; 313: 145–148.
108. Bechtold DA, Luckman SM. Prolactin-releasing peptide mediates cholecystokinin-induced satiety in mice. Endocrinology 2006; 147: 4723–4729.
109. Nicklous DM, Simansky KJ. Neuropeptide FF exerts pro-and anti-opioid actions in the parabrachial nucleus to modulate food intake. Am J Physiol-Regul Integr Comp Physiol 2003; 285: R1046–R1054.
110. Johnson MA, Tsutsui K, Fraley GS. Rat RFamide-related peptide-3 stimulates GH secretion, inhibits LH secretion, and has variable effects on sex behavior in the adult male rat. Horm Behav 2007; 51: 171–180.
111. Clarke IJ, Smith JT, Henry BA, Oldfield BJ, Stefanidis A, Millar RP, Sari IP, Chng K, Fabre-Nys C, Caraty A. Gonadotropin-inhibitory hormone is a hypothalamic peptide that provides a molecular switch between reproduction and feeding. Neuroendocrinology 2012; 95: 305–316.
112. Fu L-Y, van den Pol AN. Kisspeptin directly excites anorexigenic pomc neurons, but inhibits orexigenic npy cells by indirect synaptic mechanism. J Neurosci 2010; 30: 10205.
113. Kovács A, László K, Gálosi R, Ollmann T, Péczely L, Zagoracz O, Bencze N, Lénárd L. Intraamygdaloid microinjection of RFamide-related peptide-3 decreases food intake in rats. Brain Res Bull 2014; 107: 61–68.
114. Kovács A, László K, Gálosi R, Tóth K, Ollmann T, Péczely L, Lénárd L. Microinjection of RFRP-1 in the central nucleus of amygdala decreases food intake in the rat. Brain Res Bull 2012; 88: 589–595.
115. Desprat C, Zajac J-M. Hypothermic effects of neuropeptide FF analogues in mice. Pharmacol Biochem Behav 1997; 58: 559–563.
116. Fang Q, He F, Wang Y-Q, Guo J, Zhang B-Z, Chen Q, Wang R. Pharmacological effects of the dansylated neuropeptide FF analogues on body temperature and morphine analgesia. Neuropeptides 2007; 41: 339–347.
117. Fang Q, Wang Y-Q, He F, Guo J, Chen Q, Wang R. Inhibition of neuropeptide FF (NPFF)-induced hypothermia and anti-morphine analgesia by RF9, a new selective NPFF receptors antagonist. Regul Pept 2008; 147: 45–51.
118. Fang Q, Guo J, He F, Peng Y-L, Chang M, Wang R. In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist. Peptides 2006; 27: 2207–2213.
119. Moulédous L, Barthas F, Zajac J-M. Opposite control of body temperature by NPFF 1 and NPFF 2 receptors in mice. Neuropeptides 2010; 44: 453–456.
120. Fukusumi S, Habata Y, Yoshida H, Iijima N, Kawamata Y, Hosoya M, Fujii R, Hinuma S, Kitada C, Shintani Y. Characteristics and distribution of endogenous RFamide-related peptide-1. Biochim Biophys Acta 2001; 1540: 221–232.
121. Engström M, Brandt A, Wurster S, Savola J-M, Panula P. Prolactin releasing peptide has high affinity and efficacy at neuropeptide FF2 receptors. J Pharmacol Exp Ther 2003; 305: 825–832.
122. Yoshida H, Habata Y, Hosoya M, Kawamata Y, Kitada C, Hinuma S. Molecular properties of endogenous RFamide-related peptide-3 and its interaction with receptors. Biochim Biophys Acta 2003; 1593: 151–157.
123. 125I] EYF as selective radioligands. Neuroscience 2002; 115: 349–361.
124. Talmont F, Garcia LP, Mazarguil H, Zajac J-M, Mollereau C. Characterization of two novel tritiated radioligands for labelling Neuropeptide FF (NPFF 1 and NPFF 2) receptors. Neurochem Int 2009; 55: 815–819.
125. 35S] GTPγS binding. Neuropharmacology 2007; 52: 376–386.
126. Findeisen M, Rathmann D, Beck-Sickinger AG. Structure-activity studies of RFamide peptides reveal subtype-selective activation of neuropeptide FF1 and FF2 receptors. ChemMedChem 2011; 6: 1081–1093.
127. Lameh J, Bertozzi F, Kelly N, Jacobi PM, Nguyen D, Bajpai A, Gaubert G, Olsson R, Gardell LR. Neuropeptide FF receptors have opposing modulatory effects on nociception. J Pharmacol Exp Ther 2010; 334: 244–254.
128. Kotani M, Mollereau C, Detheux M, Le Poul E, Brézillon S, Vakili J, Mazarguil H, Vassart G, Zajac JM, Parmentier M. Functional characterization of a human receptor for neuropeptide FF and related peptides. Br J Pharmacol 2001; 133: 138–144.